LOXL2, a member of the lysyl oxidase (LOX) family, is overexpressed in multiple human malignancies including gastric cancer (Peng et al., 2009), hepatocellular carcinoma (Wong et al., 2014), breast cancer (Ahn et al., 2013), and squamous cell carcinoma (Peinado et al., 2008), where it correlates with aggressive clinicopathological features and poor prognosis. Here, LOXL2 is linked to squamous cell carcinoma.